<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02972281</url>
  </required_header>
  <id_info>
    <org_study_id>2014_07</org_study_id>
    <secondary_id>2014-A00739-38</secondary_id>
    <nct_id>NCT02972281</nct_id>
  </id_info>
  <brief_title>Systematic Search for Primary Immunodeficiency in Adults With Infections</brief_title>
  <acronym>SPIDAC</acronym>
  <official_title>Systematic Search for Primary Immunodeficiency in Adults With Unexplained Recurrent and/or Severe Infections With Encapsulated Bacteria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Imagine Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Octapharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laboratoire français de Fractionnement et de Biotechnologies</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Air Liquide SA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Binding Site Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antibody deficiencies and complement deficiencies are the most frequent Primary&#xD;
      immunodeficiencies (PIDs) in adults, and are associated with greatly increased susceptibility&#xD;
      to recurrent and/or severe bacterial infections - especially upper and lower respiratory&#xD;
      tract infections and meningitis. The literature data suggest that PIDs are under-diagnosed in&#xD;
      adults. The current European and US guidelines advocate screening adults for PIDs if they&#xD;
      present recurrent benign especially upper and lower respiratory tract infections, or if they&#xD;
      have experienced at least two severe bacterial infections and/or have a recurrent need for&#xD;
      intravenous antibiotics. The objective of the demonstrate the interest of PIDs screening in&#xD;
      adult patients who present such recurrent infections and/or after the first severe bacterial&#xD;
      infection, especially when the patients do not present with known, etiologically relevant&#xD;
      comorbidities.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    deficient inclusions&#xD;
  </why_stopped>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">March 2020</completion_date>
  <primary_completion_date type="Actual">March 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of Primary immunodeficiencies (PIDs) in adult patients with recurrent and/or severe bacterial infection with encapsulated bacteria</measure>
    <time_frame>At 6 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Complement Deficiency</condition>
  <condition>Antibody Deficiency</condition>
  <condition>Chronic Sinus Infection</condition>
  <condition>Meningitis, Bacterial</condition>
  <condition>Pneumonia, Bacterial</condition>
  <condition>Otitis Media</condition>
  <condition>Streptococcal Infection</condition>
  <condition>Neisseria Infections</condition>
  <condition>Haemophilus Influenza</condition>
  <condition>Pneumococcal Infections</condition>
  <arm_group>
    <arm_group_label>Patients with bacterial infections</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with recurrent and/or severe bacterial infections</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Immunological diagnosis tests</intervention_name>
    <description>(Non exhaustive list): hemogram, IgG, A, M, IgG subclasses, complement, vaccinal response to protein and polysaccharide antigens, ...</description>
    <arm_group_label>Patients with bacterial infections</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-65 yrs old patients&#xD;
&#xD;
          -  ≥ 2 bacterial upper or lower respiratory tract infections/years, for at least 2 years,&#xD;
             or&#xD;
&#xD;
          -  ≥ 1 severe bacterial upper or lower respiratory tract infection requiring&#xD;
             hospitalization and IV antibiotics, or&#xD;
&#xD;
          -  ≥ 1 invasive infection (meningitis, bacteriemia, arthritis) due to Streptococcus&#xD;
             pneumoniae, group A Streptococcus, Haemophilus influenzae, Neisseria meningitidis or&#xD;
             Neisseria gonorrhoeae&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  concomitant, systemic comorbidity that predisposes to infection (solid or&#xD;
             hematological cancer, diabetes mellitus, severe alcohol or intravenous drug abuse,&#xD;
             chronic liver or kidney failure, human immunodeficiency virus infection, anatomic or&#xD;
             functional asplenia, drug-induced 1 neutropenia, or solid organ or hematopoietic stem&#xD;
             cell transplantation).&#xD;
&#xD;
          -  the presence of a local predisposing factor: cigarette smoking (&gt; 5 pack-year and/or 5&#xD;
             cigarettes/day), underlying infection (tuberculosis, influenza…), chronic obstructive&#xD;
             pulmonary disease, cystic fibrosis or bronchiectasis for pulmonary infections;&#xD;
             cerebrospinal leak or preceding upper respiratory tract (URT) infections for&#xD;
             non-meningococcal meningitis; oral, dental or skin condition for GAS infections&#xD;
&#xD;
          -  use of corticosteroids, non-steroidal anti-inflammatory drugs, immunosuppressants or&#xD;
             cytotoxic chemotherapeutics&#xD;
&#xD;
          -  PID diagnosed before the infectious episode in question.&#xD;
&#xD;
          -  current or recent pregnancy&#xD;
&#xD;
          -  hospital-acquired infection (including infections of prostheses).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillaume Lefevre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ch Armentieres</name>
      <address>
        <city>Armentières</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH ARRAS</name>
      <address>
        <city>Arras</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch Boulogne-Sur-Mer</name>
      <address>
        <city>Boulogne Sur Mer</city>
        <zip>62321</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch Bethune</name>
      <address>
        <city>Béthune</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch Cambrai</name>
      <address>
        <city>Cambrai</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch Denain</name>
      <address>
        <city>Denain</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH DOUAI</name>
      <address>
        <city>Douai</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch Dunkerque</name>
      <address>
        <city>Dunkerque</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH LENS</name>
      <address>
        <city>Lens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Prive La Louviere</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU,</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Vincent - Saint Antoine</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch Arrondissement de Montreuil</name>
      <address>
        <city>Rang-du-Fliers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H de Roubaix</name>
      <address>
        <city>Roubaix</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch Region de St-Omer</name>
      <address>
        <city>Saint-Omer</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Seclin Carvin</name>
      <address>
        <city>Seclin</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch Tourcoing</name>
      <address>
        <city>Tourcoing</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch de Valenciennes</name>
      <address>
        <city>Valenciennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Teissier</name>
      <address>
        <city>Valenciennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>November 21, 2016</study_first_submitted>
  <study_first_submitted_qc>November 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2016</study_first_posted>
  <last_update_submitted>September 16, 2020</last_update_submitted>
  <last_update_submitted_qc>September 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Pneumococcal Infections</mesh_term>
    <mesh_term>Streptococcal Infections</mesh_term>
    <mesh_term>Pneumonia, Bacterial</mesh_term>
    <mesh_term>Sinusitis</mesh_term>
    <mesh_term>Meningitis, Bacterial</mesh_term>
    <mesh_term>Otitis Media</mesh_term>
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Primary Immunodeficiency Diseases</mesh_term>
    <mesh_term>Hereditary Complement Deficiency Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

